Panobinostat
Osteosarcoma
Washington University School of MedicineSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
37 Active assets in the Osteosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Milton S. Hershey Medical Center | Phase 2 | BB |
ETOPOSIDE Eisai Limited | Phase 2 | B |
Irinotecan Milton S. Hershey Medical Center | Phase 2 | B |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 2 | B |
Nivolumab Instituto do Cancer do Estado de São Paulo | Phase 2 | B |
View all 50 →
Same molecule, other indications
Panobinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →